These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Clinical and imaging metrics for monitoring disease progression in patients with multiple sclerosis. Bagnato F; Ohayon JM; Ehrmantraut M; Chiu AW; Riva M; Ikonomidou VN Expert Rev Neurother; 2006 Apr; 6(4):599-612. PubMed ID: 16623658 [TBL] [Abstract][Full Text] [Related]
25. Regional hippocampal atrophy in multiple sclerosis. Sicotte NL; Kern KC; Giesser BS; Arshanapalli A; Schultz A; Montag M; Wang H; Bookheimer SY Brain; 2008 Apr; 131(Pt 4):1134-41. PubMed ID: 18375977 [TBL] [Abstract][Full Text] [Related]
26. Brain atrophy: an in-vivo measure of disease activity in multiple sclerosis. Radü EW; Bendfeldt K; Mueller-Lenke N; Magon S; Sprenger T Swiss Med Wkly; 2013; 143():w13887. PubMed ID: 24264439 [TBL] [Abstract][Full Text] [Related]
27. Accumulation of cortical lesions in MS: relation with cognitive impairment. Roosendaal SD; Moraal B; Pouwels PJ; Vrenken H; Castelijns JA; Barkhof F; Geurts JJ Mult Scler; 2009 Jun; 15(6):708-14. PubMed ID: 19435749 [TBL] [Abstract][Full Text] [Related]
28. Cortical atrophy is relevant in multiple sclerosis at clinical onset. Calabrese M; Atzori M; Bernardi V; Morra A; Romualdi C; Rinaldi L; McAuliffe MJ; Barachino L; Perini P; Fischl B; Battistin L; Gallo P J Neurol; 2007 Sep; 254(9):1212-20. PubMed ID: 17361339 [TBL] [Abstract][Full Text] [Related]
29. In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Mainero C; Benner T; Radding A; van der Kouwe A; Jensen R; Rosen BR; Kinkel RP Neurology; 2009 Sep; 73(12):941-8. PubMed ID: 19641168 [TBL] [Abstract][Full Text] [Related]
30. Clinical correlates of grey matter pathology in multiple sclerosis. Horakova D; Kalincik T; Dusankova JB; Dolezal O BMC Neurol; 2012 Mar; 12():10. PubMed ID: 22397707 [TBL] [Abstract][Full Text] [Related]
31. Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI. Wen J; Yablonskiy DA; Luo J; Lancia S; Hildebolt C; Cross AH Neuroimage Clin; 2015; 9():164-75. PubMed ID: 27330979 [TBL] [Abstract][Full Text] [Related]
33. Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis. Amann M; Papadopoulou A; Andelova M; Magon S; Mueller-Lenke N; Naegelin Y; Stippich C; Radue EW; Bieri O; Kappos L; Sprenger T J Neurol; 2015 Aug; 262(8):1909-17. PubMed ID: 26041614 [TBL] [Abstract][Full Text] [Related]
34. MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge. Jacobsen CO; Farbu E Acta Neurol Scand Suppl; 2014; (198):32-6. PubMed ID: 24588504 [TBL] [Abstract][Full Text] [Related]
36. Relapsing and progressive forms of multiple sclerosis: insights from pathology. Dutta R; Trapp BD Curr Opin Neurol; 2014 Jun; 27(3):271-8. PubMed ID: 24722325 [TBL] [Abstract][Full Text] [Related]
37. Impact of individual cognitive profile on visuo-motor reorganization in relapsing-remitting multiple sclerosis. Gioia MC; Cerasa A; Liguori M; Passamonti L; Condino F; Vercillo L; Valentino P; Clodomiro A; Quattrone A; Fera F Brain Res; 2007 Sep; 1167():71-9. PubMed ID: 17689504 [TBL] [Abstract][Full Text] [Related]
38. The role of MRS and fMRI in multiple sclerosis. Tartaglia MC; Arnold DL Adv Neurol; 2006; 98():185-202. PubMed ID: 16400835 [TBL] [Abstract][Full Text] [Related]
39. Challenges in multiple sclerosis; how to define occurence of progression. Brinar VV; Barun B Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S30-4. PubMed ID: 24321151 [TBL] [Abstract][Full Text] [Related]
40. Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction. Lazeron RH; de Sonneville LM; Scheltens P; Polman CH; Barkhof F Mult Scler; 2006 Dec; 12(6):760-8. PubMed ID: 17263004 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]